SEO Article Directory Colorado: Cipro

Cipro is a brand name of ciprofloxacin, approved by the FDA in the following formulation(s):

CIPRO (ciprofloxacin - for suspension; oral)

Manufacturer: BAYER HLTHCARE

Approval date: September 26, 1997

Strength(s): 250MG/5ML, 500MG/5ML ^[RLD]

CIPRO (ciprofloxacin - injectable; injection)

Manufacturer: BAYER HLTHCARE

Approval date: December 26, 1990

Strength(s): 200MG/20ML (10MG/ML) ^[RLD]^[AP], 400MG/40ML (10MG/ML) ^[RLD]^[AP]

CIPRO (ciprofloxacin hydrochloride - tablet; oral)

Manufacturer: BAYER HLTHCARE

Approval date: October 22, 1987

Strength(s): EQ 250MG BASE ^[AB], EQ 500MG BASE ^[RLD]^[AB], EQ 750MG BASE ^[AB]

Manufacturer: BAYER HLTHCARE

Approval date: April 8, 1996

Strength(s): EQ 100MG BASE ^[AB]

Has a generic version of Cipro been approved?

A generic version of Cipro has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Cipro and have been approved by the FDA:

ciprofloxacin injectable; injection

Manufacturer: CLARIS LIFESCIENCES

Approval date: April 29, 2008

Strength(s): 200MG/20ML (10MG/ML) ^[AP], 400MG/40ML (10MG/ML) ^[AP]

Manufacturer: HIKMA FARMACEUTICA

Approval date: December 22, 2009

Strength(s): 200MG/20ML (10MG/ML) ^[AP], 400MG/40ML (10MG/ML) ^[AP]

Manufacturer: HOSPIRA

Approval date: August 28, 2006

Strength(s): 200MG/20ML (10MG/ML) ^[AP], 400MG/40ML (10MG/ML) ^[AP]

Manufacturer: TEVA PARENTERAL

Approval date: August 28, 2006

Strength(s): 200MG/20ML (10MG/ML) ^[AP]

ciprofloxacin hydrochloride tablet; oral

Manufacturer: APOTEX

Approval date: November 4, 2004

Strength(s): EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: AUROBINDO PHARMA

Approval date: April 26, 2007

Strength(s): EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: CARLSBAD

Approval date: June 9, 2004

Strength(s): EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: DR REDDYS LABS LTD

Approval date: June 9, 2004

Strength(s): EQ 100MG BASE ^[AB], EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: HIKMA

Approval date: June 9, 2004

Strength(s): EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: IVAX SUB TEVA PHARMS

Approval date: June 9, 2004

Strength(s): EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: June 9, 2004

Strength(s): EQ 250MG BASE ^[AB], EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: June 25, 2007

Strength(s): EQ 100MG BASE ^[AB]

Manufacturer: RANBAXY

Approval date: June 9, 2004

Strength(s): EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: TARO

Approval date: October 6, 2004

Strength(s): EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: TARO

Approval date: February 18, 2005

Strength(s): EQ 100MG BASE ^[AB]

Manufacturer: UNIQUE PHARM LABS

Approval date: September 10, 2004

Strength(s): EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: June 9, 2004

Strength(s): EQ 250MG BASE ^[AB], EQ 500MG BASE ^[AB], EQ 750MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: February 10, 2005

Strength(s): EQ 100MG BASE ^[AB]

Note: No generic formulation of the following product is available.

ciprofloxacin - for suspension; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cipro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmaceutical formulations of ciprofloxacin
Patent 5,286,754
Issued: February 15, 1994
Inventor(s): Streuff; Bernd & Luchtenberg; Helmut
Assignee(s): Bayer Aktiengesellschaft
A pharmaceutical formulation comprising by weight 30 to 95% of 1cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carb oxylic acid; 4.5 to 25% of a dry binder based on cellulose; 0 to 30% of a disintegration auxiliary based on starch; 0.5 to 10% of a disintegration auxiliary based on a cellulose derivative and/or a cross-linked polyvinyl-pyrrolidone; 0 to 2% of a flow-improving agent, and 0 to 3% of a lubricant. Tablets and capsules made from granules of the formulation, about 0.8 to 2 mm in size, exhibit high bioavailability and excellent storage stability.
Patent expiration dates:
- August 15, 2011
  ✓
  Pediatric exclusivity

Flavor-masked pharmaceutical compositions
Patent 5,695,784
Issued: December 9, 1997
Inventor(s): Pollinger; Norbert & Michaelis; Johannes & Benke; Klaus & Rupp; Roland & Bucheler; Manfred
Assignee(s): Bayer Aktiengesellschaft
The invention relates to flavour-masked pharmaceutical compositions for oral administration, their preparation and their use as medicaments. The new pharmaceutical preparations according to the invention make it possible to administer pharmaceutical active substances having very unpleasant organoleptic properties such as, for example, very bad taste, even in liquid form.
Patent expiration dates:
- December 9, 2014
- June 9, 2015
  ✓
  Pediatric exclusivity

Flavor-masked pharmaceutical compositions
Patent 6,136,347
Issued: October 24, 2000
Inventor(s): Pollinger; Norbert & Michaelis; Johannes & Benke; Klaus & Rupp; Roland & Bucheler; Manfred
Assignee(s): Bayer Aktiengesellschaft
The invention relates to flavor-masked pharmaceutical compositions for oral administration, their preparation and their use as medicaments. The new pharmaceutical preparations according to the invention make it possible to administer pharmaceutical active substances having very unpleasant organoleptic properties such as, for example, very bad taste, even in liquid form.
Patent expiration dates:
- January 6, 2013
  ✓
  Patent use: USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
- July 6, 2013
  ✓
  Pediatric exclusivity

SEO Article Directory Colorado

Monday, September 26, 2016

Cipro